{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-092465","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.045855+00:00","generated_at":"2026-05-15T19:29:46.172196+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kura Oncology Q4 2025 net loss $81M; KOMZIFTI launch revenue $2.1M in first 5 weeks","bullets":["Net loss of $81.0M in Q4 2025 vs $19.2M a year ago; full-year net loss $219.4M.","Net product revenue $2.1M from KOMZIFTI in first five weeks of commercial sales post Nov 13 FDA approval.","Collaboration revenue $15.2M (Kyowa Kirin milestones); R&D $64.4M, SG&A $39.1M.","Cash and investments $667.2M; plus $180M in anticipated Kyowa Kirin payments expected to fund through KOMET-017 Phase 3 topline (2028).","2026 milestones include updated KOMET-007 data, KOMET-015 enrollment in GIST, and darlifarnib data in KRAS G12C tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-092465","json":"https://secwatch.observer/filing/0001193125-26-092465.json","markdown":"https://secwatch.observer/filing/0001193125-26-092465.md","text":"https://secwatch.observer/filing/0001193125-26-092465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526092465/0001193125-26-092465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526092465/kura-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:29:46.172196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8816ef708e8e542bc8c37f4a0513144449fd93b2","claim":"Kura Oncology, Inc. reported the fourth quarter ended December 31, 2025 results: revenue Net product revenue: $2.1 million; Collaboration revenue: $15.2 million.","evidence_excerpt":"Fourth Quarter 2025 Financial Results • Net product revenue: $2.1 million (first five weeks of commercial sales following November 13 approval of KOMZIFTI). • Collaboration revenue: $15.2 million, compared to $53.9 million for Q4","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526092465/0001193125-26-092465-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2025"},{"label":"Revenue","value":"Net product revenue: $2.1 million; Collaboration revenue: $15.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}